Trump Administration Rolls Out Nationwide Medicaid Drug Pricing Model
The initiative aims to reduce prescription drug costs for Medicaid recipients by aligning prices with those paid in other developed nations.
President Donald Trump announced Friday that all 50 states will participate in a program designed to lower prescription drug costs within the Medicaid program. The initiative, referred to as the Medicaid "GENEROUS" model, seeks to implement Most Favored Nation pricing, capping the net price of selected drugs at levels comparable to those paid in certain other countries.
The Trump administration projects that this plan will result in billions of dollars in savings on prescription drug expenditures for Medicaid. However, experts suggest the exact savings are unclear due to the undisclosed nature of the agreements with pharmaceutical companies.
"This one thing alone should win us the midterms," Trump stated Friday, addressing reporters in the Oval Office alongside Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare & Medicaid Services Administrator Mehmet Oz. The announcement comes as concerns about the cost of living are prominent ahead of the midterm elections.
Last year, Trump signed an executive order establishing a Most Favored Nations policy, which commits the U.S. to paying prices for medications no higher than the lowest price paid by any other developed nation. In May, the White House estimated that such deals with pharmaceutical companies could save $529 billion over the next decade by lowering U.S. prescription drug prices to international levels.
While patients in Medicaid already pay nominal co-payments, the lower drug prices could benefit state budgets that contribute to funding the program. Trump indicated that states could use the resulting savings for other healthcare improvements.
Independent verification of the projected savings remains challenging because details of the agreements between the administration and participating pharmaceutical companies have not been widely publicized. Kathy Hempstead, a senior policy adviser at the Robert Wood Johnson Foundation, noted the administration faces pressure to provide more detailed data to substantiate cost-saving claims. She also raised concerns about the long-term sustainability of these price reductions once the current administration's tenure concludes.
Advocates like JD Hayworth, a former Republican congressman and spokesperson for the Pharmaceutical Reform Alliance, have acknowledged the progress but stated that the initiative is incomplete, as millions of Americans not covered by government healthcare programs also seek lower drug prices.
Drug pricing in the U.S. is influenced by factors such as treatment competition and insurance coverage. Most Americans receive prescription drug coverage through employer-sponsored plans, the individual market, or government programs like Medicaid and Medicare.